Mintz Levin Serves as Counsel to Coley Pharmaceutical Group in its IPO and Concurrent Private Placement with Pfizer Inc.BOSTON -- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC announced that it served as counsel to Wellesley, MA-based Coley coley Noun Brit an edible fish with white or grey flesh [perhaps from coalfish] Pharmaceutical Group, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : COLY coly: see mousebird. ) in its initial public offering and a concurrent private placement with Pfizer Inc. Coley's IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. consisted of 6,900,000 shares of common stock at a price of $16.00 per share, which included 900,000 shares issued upon exercise of the underwriters' over- allotment option. In a separate private placement, an additional 625,000 shares were purchased by Coley's collaboration partner, Pfizer, Inc., at $16.00 per share. Total proceeds from the IPO and private placement were $120.4 million, before commissions and expenses, with net proceeds Net Proceeds The amount received after all costs are deducted from the sale of a piece of property or security. Notes: In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions). at approximately $111.0 million. Boston-based Mintz Levin attorneys William Whelan, Megan Gates, Christopher Denn, Linda Bentley, Michael Harrington, James Chicoski, Wendy Silverman, Marianne Staniunas and Linda Rockett represented Coley Pharmaceuticals in the transaction. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC is a multidisciplinary law firm with over 450 attorneys and senior professionals in Boston, Washington D.C., Reston, VA, New York, Stamford, CT, Los Angeles and London. Mintz Levin is distinguished by its reputation for responsive client service and expertise in the areas of bankruptcy; business and finance; communications; employment; environmental; federal; health care; immigration immigration, entrance of a person (an alien) into a new country for the purpose of establishing permanent residence. Motives for immigration, like those for migration generally, are often economic, although religious or political factors may be very important. ; intellectual property; litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. ; public finance; real estate; tax; and trusts and estates. Mintz Levin's international clientele range from privately held start-ups to Fortune 100 companies in a wide array of industries including biotechnology, venture capital, telecommunications, health care and high technology. Mintz Levin was one of the first law firms to develop complementary consulting capabilities to provide complete solutions to clients' problems, including investment/wealth management, and government and public affairs. More information is available at www.mintz.com. Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR TLR Trailer TLR Toll Like Receptor (immunological research) TLR Temple (University) Law Review TLR Twin Lens Reflex TLR Texas Law Review TLR The Last Resort (gaming clan) Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases, asthma and allergy. Coley has established a pipeline of four TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Chiron, the United States government and GlaxoSmithKline. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion